Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Trends in inpatient and ICU resource utilization after CAR-T in pediatric ALL

Stephan Grupp • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T Tisagenlecleucel

Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, outlines the trends in inpatient and intensive care resource utilization after CAR T-cell therapy, either on a trial or commercially, for pediatric acute lymphoblastic leukemia (ALL) from 2012-2019 at his institute. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Stephan Grupp

1:33
Patient selection for CAR-T in ALL
Stephan Grupp • 2 Sep 2021
2:16
The latest research in ALL cellular therapy
Stephan Grupp • 2 Sep 2021
1:21
The future of treating pediatric ALL with CAR-T
Stephan Grupp • 2 Sep 2021
0:57
The importance of common language for CAR-T
Stephan Grupp • 18 Mar 2021

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:04
Increasing awareness of germline predispositions to hematological malignancies in pediatric patients
Anupama Rao • 29 Apr 2024
0:57
The development of a UK AML registry
Priyanka Mehta • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals